Get the Stockscreener App
12.48
0.79%
-0.10
After Hours:
12.70
0.22
+1.76%
Crescent Biopharma Inc stock is traded at $12.48, with a volume of 294.95K.
It is down -0.79% in the last 24 hours and down -33.62% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$12.58
Open:
$12.62
24h Volume:
294.95K
Relative Volume:
0.82
Market Cap:
$463.59M
Revenue:
$11.88M
Net Income/Loss:
$-162.08M
P/E Ratio:
-0.9997
EPS:
-12.484
Net Cash Flow:
$-156.43M
1W Performance:
-11.61%
1M Performance:
-33.62%
6M Performance:
-37.44%
1Y Performance:
+10.54%
1-Day Range:
$12.31
$13.19
1-Week Range:
$12.18
$15.28
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
12.48 | 463.59M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-01-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma Announces FDA Clearance of IND for CR-002 and Plans Global Phase 1/2 APOLLO Trial in Advanced Solid Tumors - Quiver Quantitative
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (Nasdaq:CBIO)Stock Analysis - Simply Wall Street
BetterLife Pharma Raises $100 Million in a Public Offering of Shares and Warrants - Yahoo Finance
Planned 804-share sale at Crescent Biopharma (Nasdaq: CBIO) - Stock Titan
Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Certain Options of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com Canada
Crescent Biopharma at Cantor conference: global trial push - Investing.com India
Crescent Biopharma at Cantor conference: global trial push - investing.com
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsTRIN Signal - siam.in
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsStatistical Arbitrage - dars.gov.et
Crescent Biopharma Announces September 2026 Investor Conference Presentations - quiverquant.com
Crescent Biopharma to Present at September Investor Conferences - GlobeNewswire
Crescent Biopharma to Present at September Investor Conferences - Yahoo Finance
Crescent Capital (CCAP) holder sells at about $10.50 under trading plan - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma posts $24.8 million Q2 net loss - quiverquant.com
CBIO Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Stock DeclinesEPS Guidance Update - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management ImprovesEarnings Quality Score - vinanet.vn
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crescent Biopharma Inc Stock (CBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Joshua T Brumm | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
9,013 |
154,843 |
0 |
| Jonathan McNeill | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
4,415 |
75,850 |
0 |
| McNeill Jonathan | President and COO |
Sep 18 '26 |
Sale |
16.71 |
3,839 |
64,150 |
134,588 |
| Brumm Joshua T | Chief Executive Officer |
Sep 18 '26 |
Sale |
16.71 |
7,837 |
130,956 |
271,765 |
| Brumm Joshua T | Chief Executive Officer |
Sep 16 '26 |
Sale |
17.90 |
1,610 |
28,819 |
279,602 |
| McNeill Jonathan | President and COO |
Sep 16 '26 |
Sale |
17.90 |
731 |
13,085 |
138,427 |
| Jonathan McNeill | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
804 |
15,115 |
0 |
| Joshua T Brumm | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
1,771 |
33,295 |
0 |
| Pinkas Jan | Chief Scientific Officer |
Sep 16 '26 |
Sale |
17.90 |
658 |
11,778 |
21,581 |
| Im Ellie Eunkyung | Chief Medical Officer |
Sep 16 '26 |
Sale |
17.90 |
623 |
11,152 |
21,446 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):